3.5.4 EHC18 (Enzo Immune Regulator)

In November 2000, Enzo Biochem, Inc., announced Israel’s approval to start a Phase I human clinical trial to test the safety and efficacy of a treatment for chronic Hep C patients or for those with liver cancer. The product, EHC18, is a broad-spectrum immune regulation medicine developed by Enzo, which stems from the company’s work with EHT899 for treating hepatitis B. The results have shown the product to be safe, and further study is being discussed ( www.enzo.com).